Gleevec® recognized as “Discovery of the Decade” for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
Basel, November 2, 2016 /3BL Media/ – Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation “Discovery of the Decade” Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.
HOUSTON, October 18, 2016 /3BL Media/ - The National Diversity Council is proud to present “Leading While Diverse: The Case for Diversity in Corporate Governance,” a comprehensive research report ranking top pharmaceutical companies based on their diversity in executive positions and boards of directors. The reputation of multinational pharmaceutical companies is currently one of the lowest, second only to health insurance companies.
Access to healthcare is making controversial headlines these days as the report of the High-Level Panel on Access to Medicines set up by the Secretary-General of the United Nations was just released. We need to move away from ideological disputes about intellectual property and focus on how we can help patients receive the treatments they need now.
Any solution to the access challenge needs to consider the complex factors that affect access in developing countries. It would indeed be misleading and counter-productive to focus the access debate on patents. (...)
By David Reddy, CEO, Medicines for Malaria Venture and Jürgen Brokatzky-Geiger, Global Head of Corporate Responsibility, Novartis
No child should ever die from a mosquito bite. Yet, today, in an era of extraordinary medical advancement, a child dies of mosquito-borne malaria every two minutes. Last year, this agonizing blood disease caused by the malaria parasite claimed nearly half a million lives—most of them children.